These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 33544122)

  • 1. Subclinical Pulmonary Involvement in Active IBD Responds to Biologic Therapy.
    Ellrichmann M; Bethge J; Boesenkoetter J; Conrad C; Noth R; Bahmer T; Nikolaus S; Aden K; Zeissig S; Schreiber S
    J Crohns Colitis; 2021 Aug; 15(8):1339-1345. PubMed ID: 33544122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The role of biologic therapy in the treatment of extraintestinal manifestations and complications of inflammatory bowel disease].
    Kujundzić M
    Acta Med Croatica; 2013 Apr; 67(2):195-201. PubMed ID: 24471303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visceral adiposity and inflammatory bowel disease.
    Rowan CR; McManus J; Boland K; O'Toole A
    Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations in pulmonary function in inflammatory bowel disease are frequent and persist during remission.
    Herrlinger KR; Noftz MK; Dalhoff K; Ludwig D; Stange EF; Fellermann K
    Am J Gastroenterol; 2002 Feb; 97(2):377-81. PubMed ID: 11866276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of axial spondyloarthritis after one year of anti-tumor necrosis factor therapy among patients with inflammatory bowel diseases.
    Dalal RS; Ermann J; Carlin A; Mitri J; Allegretti JR
    Clin Rheumatol; 2023 Nov; 42(11):3001-3006. PubMed ID: 37428414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.
    Targownik LE; Benchimol EI; Bernstein CN; Singh H; Lix L; Tennakoon A; Leung S; Aviña A; Coward S; Jones J; Kaplan G; Murthy SK; Nguyen GC; Peña-Sánchez JN
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1788-1798.e2. PubMed ID: 30448599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases.
    Aden K; Rehman A; Waschina S; Pan WH; Walker A; Lucio M; Nunez AM; Bharti R; Zimmerman J; Bethge J; Schulte B; Schulte D; Franke A; Nikolaus S; Schroeder JO; Vandeputte D; Raes J; Szymczak S; Waetzig GH; Zeuner R; Schmitt-Kopplin P; Kaleta C; Schreiber S; Rosenstiel P
    Gastroenterology; 2019 Nov; 157(5):1279-1292.e11. PubMed ID: 31326413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary Function Tests Abnormalities in Children With Inflammatory Bowel Disease: Is It Common?
    El Amrousy DM; Hassan S; El-Ashry H; Yousef M; Sharshar R
    J Pediatr Gastroenterol Nutr; 2018 Sep; 67(3):346-350. PubMed ID: 29620595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammatory Bowel Disease Patients Who Respond to Treatment with Anti-tumor Necrosis Factor Agents Demonstrate Improvement in Pre-treatment Frailty.
    Kochar BD; Cai W; Ananthakrishnan AN
    Dig Dis Sci; 2022 Feb; 67(2):622-628. PubMed ID: 33932198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained clinical benefit, improved quality of life, and reduced intestinal surgery from maintenance infliximab treatment in inflammatory bowel disease
    Hossain A; Lördal M; Olsson AE; Storlåhls A; Aleman S; Eberhardson M; Befrits R
    Scand J Gastroenterol; 2020 Feb; 55(2):178-183. PubMed ID: 32052663
    [No Abstract]   [Full Text] [Related]  

  • 11. Increased Discontinuation Rates of Anti-TNF Therapy in Elderly Inflammatory Bowel Disease Patients.
    de Jong ME; Smits LJT; van Ruijven B; den Broeder N; Russel MGVM; Römkens TEH; West RL; Jansen JM; Hoentjen F
    J Crohns Colitis; 2020 Jul; 14(7):888-895. PubMed ID: 31974546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications.
    Targownik LE; Benchimol EI; Bernstein CN; Singh H; Tennakoon A; Zubieta AA; Coward S; Jones J; Kaplan GG; Kuenzig ME; Murthy SK; Nguyen GC; Peña-Sánchez JN
    J Crohns Colitis; 2020 Oct; 14(10):1354-1363. PubMed ID: 32648579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. INFLIXIMAB AND ADALIMUMAB SERUM TROUGH CONCENTRATIONS THRESHOLD ASSOCIATED WITH DEEP REMISSION IN INFLAMMATORY BOWEL DISEASE.
    Pascual-Marmaneu Ó; Belles-Medall MD; Ferrando-Piqueres R; Almela-Notari P; Mendoza-Aguilera M; Álvarez-Martín T
    Farm Hosp; 2021 Aug; 45(5):225-233. PubMed ID: 34806581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of Occult Pulmonary Involvement in Ulcerative Colitis.
    Gupta SJ; Gupta VL; Kothari HG; Samarth AR; Gaikwad NR; Parmar SM
    Inflamm Intest Dis; 2020 Aug; 5(3):144-150. PubMed ID: 32999887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
    Chaparro M; Barreiro-de Acosta M; Echarri A; Almendros R; Barrio J; Llao J; Gomollón F; Vera M; Cabriada JL; Guardiola J; Guerra I; Beltrán B; Roncero O; Busquets D; Taxonera C; Calvet X; Ferreiro-Iglesias R; Ollero Pena V; Bernardo D; Donday MG; Garre A; Godino A; Díaz A; Gisbert JP
    Dig Dis Sci; 2019 Mar; 64(3):846-854. PubMed ID: 30426297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor α antagonists.
    Guo A; Ross C; Chande N; Gregor J; Ponich T; Khanna R; Sey M; Beaton M; Yan B; Kim RB; Wilson A
    Sci Rep; 2022 Jan; 12(1):1185. PubMed ID: 35075155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study.
    Murthy SK; Begum J; Benchimol EI; Bernstein CN; Kaplan GG; McCurdy JD; Singh H; Targownik L; Taljaard M
    Gut; 2020 Feb; 69(2):274-282. PubMed ID: 31196874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of fecal calprotectin and serum C-reactive protein in early prediction of outcome to infliximab induction therapy.
    Engström J; Lönnkvist M; Befrits R; Ljung T; Diaz-Tartera H; Holst M; Hellström PM
    Scand J Gastroenterol; 2019 Sep; 54(9):1081-1088. PubMed ID: 31499013
    [No Abstract]   [Full Text] [Related]  

  • 19. Pulmonary function in patients with ulcerative colitis and its relationship with disease severity.
    Goyal A; Ghoshal UC; Nath A; Jindal S; Mohindra S
    JGH Open; 2017 Sep; 1(1):32-37. PubMed ID: 30483530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of suboptimal response to tumor necrosis factor antagonist therapy in inflammatory bowel disease in newly industrialised countries: The EXPLORE study.
    Yamamoto-Furusho JK; Al Harbi O; Armuzzi A; Chan W; Ponce de Leon E; Qian J; Shapina M; Toruner M; Tu CH; Ye BD; Guennec M; Sison C; Demuth D; Fadeeva O; Khan QMR
    Dig Liver Dis; 2020 Aug; 52(8):869-877. PubMed ID: 32563721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.